ATE236255T1 - Impfstoff gegen den hepatitis e-virus und verfahren - Google Patents

Impfstoff gegen den hepatitis e-virus und verfahren

Info

Publication number
ATE236255T1
ATE236255T1 AT93911555T AT93911555T ATE236255T1 AT E236255 T1 ATE236255 T1 AT E236255T1 AT 93911555 T AT93911555 T AT 93911555T AT 93911555 T AT93911555 T AT 93911555T AT E236255 T1 ATE236255 T1 AT E236255T1
Authority
AT
Austria
Prior art keywords
hev
effective
antibody
infection
composition
Prior art date
Application number
AT93911555T
Other languages
English (en)
Inventor
Gregory R Reyes
Daniel W Bradley
Jr-Shin Twu
Michael A Purdy
Albert W Tam
Krzysztof Z Krawczynski
Patrice O Yarbough
Original Assignee
Genelabs Tech Inc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc, Us Gov Health & Human Serv filed Critical Genelabs Tech Inc
Application granted granted Critical
Publication of ATE236255T1 publication Critical patent/ATE236255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93911555T 1992-01-17 1993-01-15 Impfstoff gegen den hepatitis e-virus und verfahren ATE236255T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82233592A 1992-01-17 1992-01-17
US07/870,985 US6455492B1 (en) 1988-06-17 1992-04-20 Hepatitis E virus vaccine and method
PCT/US1993/000475 WO1993014208A2 (en) 1992-01-17 1993-01-19 Hepatitis e virus vaccine and method

Publications (1)

Publication Number Publication Date
ATE236255T1 true ATE236255T1 (de) 2003-04-15

Family

ID=27124631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911555T ATE236255T1 (de) 1992-01-17 1993-01-15 Impfstoff gegen den hepatitis e-virus und verfahren

Country Status (9)

Country Link
US (3) US6455492B1 (de)
EP (1) EP0623169B1 (de)
JP (2) JP3746291B2 (de)
AT (1) ATE236255T1 (de)
CA (1) CA2125701A1 (de)
DE (1) DE69332820T2 (de)
DK (1) DK0623169T3 (de)
ES (1) ES2196008T3 (de)
WO (1) WO1993014208A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214970B1 (en) 1988-06-17 2001-04-10 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5789559A (en) * 1988-06-17 1998-08-04 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
US6291641B1 (en) 1988-06-17 2001-09-18 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5686239A (en) * 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US6455492B1 (en) * 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US6787145B1 (en) 1992-09-18 2004-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
WO1994006913A2 (en) * 1992-09-18 1994-03-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
US6207416B1 (en) 1992-09-18 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US5736315A (en) * 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
US5563032A (en) * 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
DE69435059D1 (de) * 1993-09-24 2008-02-14 Macfarlane Burnet Inst For Med Immunoreaktive antigene des hepatitis e viruses
JPH09507749A (ja) * 1993-12-22 1997-08-12 アボツト・ラボラトリーズ Ｅ型肝炎ウイルスに対するモノクローナル抗体及びそれらを使用する方法
US5830636A (en) * 1993-12-22 1998-11-03 Abbott Laboratories HEV orf-2 monoclonal antibodies and methods for using same
AU1437695A (en) * 1993-12-22 1995-07-10 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same
US6054567A (en) * 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US6458562B1 (en) 1998-04-09 2002-10-01 The United States Of America As Represented By The Secretary Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
CA2283538A1 (en) * 1999-09-30 2001-03-30 Mun Hon Ng New hev antigenic peptide and methods
US7005130B2 (en) * 2001-01-05 2006-02-28 Virginia Tech Intellectual Properties, Inc. Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E
US20030220475A1 (en) * 2001-04-03 2003-11-27 Fields Howard A. Neutralizing immunogenic hev polypepetides
US6614586B2 (en) * 2001-07-30 2003-09-02 Dorsal Networks, Inc. Methods and systems for high performance, wide bandwidth optical communication systems using Raman amplification
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2493249C1 (ru) * 2012-04-27 2013-09-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей hansenula polymorpha - продуцент капсидного белка вируса гепатита е
RU2501809C1 (ru) * 2012-04-27 2013-12-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантного капсидного белка вируса гепатита е и рекомбинантная вакцина для профилактики вирусного гепатита е
RU2501568C1 (ru) * 2012-04-27 2013-12-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита е у животных
CN112384530B (zh) * 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218099A (en) * 1986-04-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Post-transfusion, non-A, non-B hepatitis virus polynucleotides
FR2597606B1 (fr) * 1986-04-16 1989-10-06 Pasteur Institut Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique
US5686239A (en) * 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US6455492B1 (en) * 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US5741490A (en) * 1988-06-17 1998-04-21 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US5885768A (en) * 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US5202430A (en) * 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
KR0178399B1 (ko) * 1990-04-05 1999-04-01 프랭크 쿵 장을 통해 전염되는 비a비b형 간염 바이러스 병원체 및 그것의 특유한 에피토프
JPH04200388A (ja) * 1990-11-29 1992-07-21 Chemo Sero Therapeut Res Inst 流行性非ａ非ｂ型肝炎ウイルス抗原ペプチドおよびこれをコードする核酸断片
WO1994006913A2 (en) * 1992-09-18 1994-03-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines

Also Published As

Publication number Publication date
JP3746291B2 (ja) 2006-02-15
WO1993014208A2 (en) 1993-07-22
CA2125701A1 (en) 1993-07-22
JP2006036795A (ja) 2006-02-09
EP0623169B1 (de) 2003-04-02
US6455492B1 (en) 2002-09-24
DE69332820D1 (de) 2003-05-08
US5770689A (en) 1998-06-23
DE69332820T2 (de) 2004-01-29
DK0623169T3 (da) 2003-07-21
WO1993014208A3 (en) 1993-10-14
ES2196008T3 (es) 2003-12-16
EP0623169A1 (de) 1994-11-09
US20030143241A1 (en) 2003-07-31
JPH08509201A (ja) 1996-10-01

Similar Documents

Publication Publication Date Title
DE69332820T2 (de) Impfstoff gegen den hepatitis e-virus und verfahren
LU91393I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
DE60043708D1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
DE69111801D1 (de) Vakzin gegen hepatitis b.
EP1200109A4 (de) Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
LU91323I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
IT1278077B1 (it) Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
ATE449178T1 (de) Rekombinante proteine eines pakistani stammes von hepatitis e-virus sowie ihre verwendung in diagnostischen verfahren und als vakzine
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
FI931393A7 (fi) Peptidit käytettäväksi rokotuksessa ja neutraloivien vasta-aineiden in duktiossa ihmisen immuunikadon aiheuttavaa virusta vastaan
DK345685A (da) Hepatitis b vaccine
DE69030383D1 (de) Impfstoff-Konjugate zur Behandlung von Vogelkrankheiten
MX9603182A (es) Vacuna de hepatitis b.
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
EP0344864A3 (de) Verfahren zur Herstellung von nicht-hyperglycosylierten Hepatitis B Virusproteinen
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
ATE518879T1 (de) Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus
Grose et al. Immunogenic glycoproteins of laboratory and vaccine strains of varicella-zoster virus
FI923020A0 (fi) Inte a inte b-sekvenser.
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
NO933897L (no) HBV-overflateproteiner med redusert vertskarbohydrat
EP1274851A4 (de) Für eine prozessierungskomponente aus der n-terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0623169

Country of ref document: EP

REN Ceased due to non-payment of the annual fee